Oak Ridge Investments LLC Boosts Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Oak Ridge Investments LLC grew its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 74.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 19,831 shares of the biopharmaceutical company's stock after buying an additional 8,440 shares during the quarter. Oak Ridge Investments LLC's holdings in Intra-Cellular Therapies were worth $1,656,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Barclays PLC grew its holdings in Intra-Cellular Therapies by 282.0% during the 3rd quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company's stock worth $2,521,000 after acquiring an additional 25,435 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in shares of Intra-Cellular Therapies by 31.9% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 454,538 shares of the biopharmaceutical company's stock worth $33,258,000 after purchasing an additional 109,892 shares in the last quarter. Principal Financial Group Inc. raised its stake in Intra-Cellular Therapies by 3.3% in the third quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company's stock valued at $43,735,000 after buying an additional 18,865 shares in the last quarter. TimesSquare Capital Management LLC lifted its holdings in Intra-Cellular Therapies by 6.5% during the 3rd quarter. TimesSquare Capital Management LLC now owns 438,083 shares of the biopharmaceutical company's stock worth $32,055,000 after buying an additional 26,600 shares during the last quarter. Finally, Cynosure Group LLC boosted its position in shares of Intra-Cellular Therapies by 161.0% during the 3rd quarter. Cynosure Group LLC now owns 14,442 shares of the biopharmaceutical company's stock worth $1,057,000 after acquiring an additional 8,909 shares in the last quarter. 92.33% of the stock is owned by institutional investors and hedge funds.

Intra-Cellular Therapies Price Performance

Shares of ITCI stock traded down $0.06 during midday trading on Friday, hitting $126.20. The company had a trading volume of 6,016,325 shares, compared to its average volume of 451,954. Intra-Cellular Therapies, Inc. has a 52-week low of $62.78 and a 52-week high of $128.00. The company's 50 day simple moving average is $89.30 and its 200 day simple moving average is $80.90. The stock has a market cap of $13.38 billion, a price-to-earnings ratio of -145.06 and a beta of 0.70.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The firm had revenue of $175.40 million during the quarter, compared to analyst estimates of $172.30 million. During the same period in the prior year, the firm posted ($0.25) earnings per share. The business's quarterly revenue was up 39.0% compared to the same quarter last year. Analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Insider Transactions at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 51,000 shares of Intra-Cellular Therapies stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $85.80, for a total value of $4,375,800.00. Following the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, President Michael Halstead sold 22,869 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $89.12, for a total value of $2,038,085.28. The disclosure for this sale can be found here. Company insiders own 2.60% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ITCI shares. Needham & Company LLC reissued a "hold" rating and set a $100.00 target price on shares of Intra-Cellular Therapies in a research report on Monday, January 13th. Leerink Partnrs cut shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a report on Monday, January 13th. Baird R W lowered shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Piper Sandler reaffirmed a "neutral" rating and set a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Finally, Morgan Stanley boosted their target price on Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Six research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $100.31.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.